Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.40 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689334 | 1.00 | SPHK1 (0.49) | SPHK1AGTR2KDM4EESR2KCNH2 | |
| SCHEMBL5689661 | 0.87 | KDM4E (0.52) | SPHK1KDM4EGRIN2B | |
| SCHEMBL6841392 | 0.87 | KDM4E (0.56) | SPHK1KDM4EGRIN2B | |
| SCHEMBL5689666 | 0.87 | KDM4E (0.52) | SPHK1KDM4EGRIN2B | |
| SCHEMBL6836225 | 0.87 | KDM4E (0.56) | SPHK1KDM4EGRIN2B | |
| SCHEMBL7023319 | 0.87 | KDM4E (0.52) | SPHK1KDM4EGRIN2B | |
| SCHEMBL6840856 | 0.84 | KDM4E (0.54) | SPHK1KDM4EGRIN2B | |
| SCHEMBL6840853 | 0.84 | KDM4E (0.54) | SPHK1KDM4EGRIN2B | |
| SCHEMBL5690171 | 0.82 | BCHE (0.47) | SPHK1KDM4EGRIN2BALOX5 | |
| SCHEMBL5690175 | 0.82 | BCHE (0.47) | SPHK1KDM4EGRIN2BALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0982026-B1 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | claimed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | claimed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | claimed |
| EP-0982026-B1 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | disclosed |